Combining insulin and oral agents in diabetes: indications and controversies.
Where this comes from
- Record sourced from PubMed, PMID 1456195.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Patients with noninsulin-dependent diabetes demonstrate peripheral insulin resistance that is aggravated by increased hepatic glucose production and results in elevated serum insulin and serum glucose levels. These levels can be affected by intensive diabetic management, including diet, exercise, lifestyle modifications and insulin or sulfonylurea therapy. Sulfonylureas stimulate endogenous insulin production, increase peripheral sensitivity to insulin and suppress hepatic glucose production. In spite of its added expense, increased potential for side effects and questionable efficacy, combination therapy with insulin and a sulfonylurea is often considered in noninsulin-dependent diabetics with difficult-to-control disease.